Twinbeech Capital LP Raises Stake in Humana Inc. (NYSE:HUM)

Twinbeech Capital LP grew its position in Humana Inc. (NYSE:HUM - Free Report) by 41.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 183,034 shares of the insurance provider's stock after buying an additional 53,863 shares during the period. Twinbeech Capital LP owned approximately 0.15% of Humana worth $46,438,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Humana by 15.8% in the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock worth $3,254,899,000 after buying an additional 1,751,857 shares during the last quarter. Dodge & Cox raised its holdings in Humana by 106.7% in the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after buying an additional 5,264,045 shares during the last quarter. Pzena Investment Management LLC raised its holdings in Humana by 44.0% in the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock worth $915,736,000 after buying an additional 1,103,132 shares during the last quarter. Geode Capital Management LLC raised its holdings in Humana by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider's stock worth $729,658,000 after buying an additional 63,562 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in Humana by 29.8% in the fourth quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider's stock worth $608,348,000 after buying an additional 550,692 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Performance

Shares of NYSE HUM opened at $237.42 on Monday. The firm has a fifty day moving average price of $262.94 and a 200-day moving average price of $269.57. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a market cap of $28.65 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 2.05 and a beta of 0.49. Humana Inc. has a 1 year low of $212.45 and a 1 year high of $406.46.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.07 by $1.51. The firm had revenue of $32.11 billion during the quarter, compared to analysts' expectations of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. The company's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the prior year, the company posted $7.23 earnings per share. Equities analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.49%. Humana's dividend payout ratio (DPR) is presently 25.04%.

Analyst Ratings Changes

Several research analysts have issued reports on HUM shares. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $283.00 target price on shares of Humana in a report on Wednesday, February 12th. Mizuho lifted their target price on shares of Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a report on Wednesday, April 9th. Raymond James raised shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective for the company in a report on Thursday, May 1st. Truist Financial decreased their price objective on shares of Humana from $325.00 to $305.00 and set a "hold" rating for the company in a report on Monday, May 12th. Finally, Oppenheimer boosted their price objective on shares of Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a report on Thursday, May 1st. Seventeen equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $286.81.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.